Data as of 2026-09-16.
"Blood cancer" covers three broad lineages: the leukemias (acute and chronic, myeloid and lymphoid), the lymphomas (Hodgkin and non-Hodgkin), and plasma-cell and myeloid neoplasms (multiple myeloma, MDS, myelofibrosis). These are the leading edge of cell and immune therapy — CAR-T, bispecific antibodies, and targeted small molecules — and many programs move across several subtypes at once. A complete hematologic view tracks the major lineages and the high-volume subtypes together.
Categories overlap (leukemia includes AML/ALL/CLL; the lymphoma total is the full lymphoma hub), so the rows below do not sum to the total above. Each links to a dedicated landscape page.
Major categories
| Subtype | Active | Recruiting | Phase 3 |
|---|---|---|---|
| Leukemia (all types) | 2162 | 1254 | 191 |
| Lymphoma (all types) | 2327 | 1292 | 203 |
| Multiple Myeloma | 1029 | 546 | 122 |
| Myelodysplastic Syndromes (MDS) | 561 | 328 | 41 |
| Myelofibrosis | 142 | 83 | 14 |
Leukemia subtypes
| Subtype | Active | Recruiting | Phase 3 |
|---|---|---|---|
| Acute Myeloid Leukemia (AML) | 999 | 586 | 95 |
| Acute Lymphoblastic Leukemia (ALL) | 753 | 450 | 57 |
| Chronic Lymphocytic Leukemia (CLL) | 390 | 191 | 44 |
Track every new blood cancer trial automatically
ClinicalTrials.gov updates daily. Our pipeline monitors it for you and delivers a clean digest every morning.
Get the free digest, no credit cardLargest industry-sponsored blood cancer trial portfolios by active study count:
| Industry sponsor | Active trials |
|---|---|
| Bristol-Myers Squibb | 52 |
| Johnson & Johnson / Janssen | 50 |
| AbbVie | 45 |
| AstraZeneca | 37 |
| Novartis Pharmaceuticals | 32 |
Our pipeline pulls from ClinicalTrials.gov every day. For a blood cancer watchlist or saved search, your digest covers:
- New study registrations and status changes (for example opened to recruiting, completed)
- Protocol changes: enrollment, endpoints, phase, and completion-date movements
- New sponsor entrants into a subtype
- Phase filters (Phase 1 for novel mechanisms, Phase 3 for registration programs)
- Sponsor-type filters (large pharma vs. emerging biotech vs. academic)
Ready to automate your blood cancer trial monitoring?
Free plan, no credit card required. Set up your profile in 2 minutes.
Start freeFrequently asked questions
DataLookout checks ClinicalTrials.gov every day and records what changed on each trial: status, enrollment, phase, primary endpoint, completion dates, sites, sponsor, and the stated reason a trial stopped. Add a sponsor or a disease to your watchlist, or save any search, and the changes arrive in a daily or weekly email digest.
Free, $0 forever: 1 sponsor + 1 disease watchlist, 1 saved search in your email digest, track up to 5 individual trials, daily change detection, Trials at Risk (top trial). No credit card.
Starter, $49/month: 3 sponsor + 3 disease watchlists, 3 saved searches in your email digest, track up to 25 individual trials, full Trials at Risk list and landscape reports.
Pro, $149/month: unlimited sponsor and disease watchlists, unlimited saved searches, track unlimited individual trials, CSV export, priority email support.
Data as of 2026-09-16, from ClinicalTrials.gov. View the full pipeline on the dashboard.